Table 3 Association between SU levels and mortality, AMI incidence, stroke incidence and ESRF incidence

Per 100-µmol/L increase in continuous SU

1.17 (1.12–1.24)

1.14 (1.09–1.20)

1.16 (1.07–1.25)

1.13 (1.05–1.22)

0.95 (0.85–1.06)

0.94 (0.85–1.05)

1.49 (1.37–1.63)

1.33 (1.22–1.44)

Quartile 1 [108–400µmol/L]

1.26 (1.02–1.56)

1.11 (0.89–1.37)

1.15 (0.85–1.56)

1.07 (0.79–1.45)

1.08 (0.73–1.60)

0.99 (0.67–1.47)

1.16 (0.72–1.89)

1.07 (0.66–1.75)

Quartile 2 [400–493µmol/L]

Ref

Ref

Ref

Ref

Ref

Ref

Ref

Ref

Quartile 3 [493–580µmol/L]

1.20 (0.97–1.48)

1.31 (1.06–1.62)

1.11 (0.82–1.51)

1.18 (0.87–1.60)

0.88 (0.59–1.33)

0.92 (0.61–1.39)

1.73 (1.11–2.71)

1.85 (1.18–2.89)

Quartile 4 [580–1250µmol/L]

1.86 (1.53–2.27)

1.66 (1.36–2.03)

1.58 (1.18–2.11)

1.42 (1.06–1.91)

1.12 (0.75–1.66)

1.05 (0.70–1.57)

3.96 (2.65–5.92)

3.02 (2.00–4.56)

P-trend

< 0.001

< 0.001

0.004

0.017

0.832

0.923

< 0.001

< 0.001